ETFs SynAct Pharma AB

SYNACT

SE0008241491

Pharmaceuticals

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-21 EDT			5-day change	1st Jan Change
17.44 ^SEK	+1.63%		+1.40%	-22.83%

09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI

ETFs positioned on SynAct Pharma AB

Name		YTD change	Weight	AuM
STATE STREET SPDR PORTFOLIO EUROPE ETF - USD		+3.86%	0%	742 M€

SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

11-01 Earnings release - Q3 2026

More about the company